Valproate sodium

ApprovedSmall molecule

Sanofi

Valproate sodium is one of 176 small molecule programs targeting Brain Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryActive, not recruiting

SeizureActive, not recruiting

MigraineActive, not recruiting

EpilepsyActive, not recruiting

Bipolar DisorderActive, not recruiting

Brain InjuryApproved

Active, not recruiting

SeizurePhase 3

Active, not recruiting

MigrainePhase 3

Active, not recruiting

EpilepsyApproved

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Valproate sodium

Sanofi

Approved

1 2

Aimovig

Amgen

Preclinical

33 3

Savella

AbbVie

Preclinical

2 4

Bayer Aspirin

Bayer

Preclinical

2 5

Botox

RRevance Therapeutics, Inc.

Preclinical

9 6

Adempas

Bayer

Preclinical

1 7

Cervidil

Pfizer

Preclinical

1 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 9

Nitrostat

VViatris Specialty LLC

Preclinical

2 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epilepsy1 trial

Study of Valproate in Young Patients Suffering From Epilepsy

Completed· Sanofi logo

Sanofi·Phase 4·NCT00385411·81 enrolled

Migraine1 trial

Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.

Completed·UUniversidad Autonoma de San Luis Potosí·Phase 3·NCT04698525·33 enrolled

Treatment1 trial

Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment

Unknown status·SSun Yat-sen University··NCT01172626·150 enrolled

Seizure1 trial

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00004817·385 enrolled

Bipolar Disorder1 trial

VALID : VAlproate Versus LIthium in Bipolar Disorders

Completed· Sanofi logo

Sanofi·Phase 4·NCT00264173·270 enrolled

1 more indication

Brain Injury1 trial

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT06081283·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Valproate sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Valproate sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Valproate sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Valproate sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epilepsy1 trial

Migraine1 trial

Treatment1 trial

Seizure1 trial

Bipolar Disorder1 trial

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News